1362 / 1631
➢
The addition of adjuvant novel agents to RT, such as proteasome
inhibitors or immunomodulatory drugs (eg, lenalidomide), is a
theoretically attractive approach, both in enhancing local control and
possibly eradicating subclinical disease in patients with SP to prevent
the development of systemic MM
➢
Preliminary data suggest feasibility and effectiveness of a combined
approach
➢
This approach will be under active investigation in the United Kingdom
in a phase 3 study, examining the potential role of lenalidomide with
dexamethasone in improving progression-free survival
Future directions